The September 2026 edition of the Givens Health Venture Report captures a month of institutional follow-through and quiet capital-building within the Texas innovation ecosystem. The CPRIT platform overhaul flagged as a process story last issue reached its next milestone, as the agency opened the first module of its new Grant Management Platform on schedule, closing the book on a fragmented, decade-old application system and setting a hard January 2027 deadline for the remaining legacy tools to retire.

Against that quieter institutional backdrop, the state's headline story wasn't a closed deal at all: Dallas-based Colossal Biosciences emerged as reportedly in talks to raise new capital at a $20 billion to $30 billion valuation, a two-to-three-times step-up from its $10.2 billion mark set just sixteen months earlier. On the financing side that did close, Austin's Happy Health raised a $75 million Series A led by ARCH Venture Partners and OpenLoop to scale its FDA-cleared smart-ring platform into home-based sleep care. As capital concentrated around fewer, larger stories, this month's report also tracks the seed-stage activity still filling in behind them, epitomized by Austin's INNOVOTEX and its $4 million round to advance texaphyrin-based oncology therapeutics.

The August 2026 edition of the Givens Health Venture Report captures a month of resolution and capital concentration within the Texas innovation ecosystem. The Hill County data center saga that defined last month's friction came to a close, as developer RCM Hill dismissed its $100 million lawsuit with prejudice, closing the book on Texas's first county-level data center moratorium and clarifying the legal limits of local resistance to Big Tech's grid consumption.

Against that resolution, the state's healthcare sector delivered its biggest headlines yet: Austin's Function Health closed a $450 million non-dilutive growth round from General Catalyst just eight months after its $298 million Series B, and Dallas-based Forte Biosciences was acquired by Amsterdam's Agenx for $2.2 billion. This is the largest Texas healthcare exit of the month. As capital continues to reward commercially de-risked, clinically validated platforms, this month's report also tracks high-conviction, early-stage deployments defining the region, epitomized by Houston's TYBR Health and its $30 million Series A.

The June 2026 edition of the Givens Health Venture Report captures the moment Texas biotech proved it could compete for the country's largest venture checks. Austin-based Ollin Biosciences closed an oversubscribed $330 million Series B (one of the biggest biotech rounds in the U.S. this year) backed by a syndicate of national life-sciences heavyweights including ARCH Venture Partners and TCGX, to push its retinal-disease antibody into global Phase 3 trials.

Against that backdrop, the Hill County data center standoff reached its first resolution: commissioners rescinded the state's first county-level moratorium just two weeks after passing it, trading a blunt construction freeze for a developer disclosure checklist. The report also tracks Texas capital's growing reach beyond its own borders, as Austin's S3Ventures co-led an $31 million medtech round outside the state, a sign that Texas healthcare investors are now exporting capital as readily as they attract it.

The June 2026 edition of the Givens Health Venture Report explores a defining moment of structural friction and capital opportunity within the Texas innovation ecosystem. While the Hill County’s historic data center construction moratorium and the subsequent $100 million developer lawsuit signal intense local resistance to Big Tech’s rapid grid consumption, the state's healthcare sector is emerging as a resilient, highly capitalized safe haven.

This evolution is driven by a monumental $103 million state injection from CPRIT, alongside critical institutional milestones like UT Austin’s dual appointments in clinical AI and venture entrepreneurship. As capital aggressively shifts toward deep clinical quality, this month's report analyzes the high-conviction, early-stage deployments defining the region, epitomized by Secretome Therapeutics’ landmark $30 million Series A.

This inaugural issue of The Givens Health Venture Report analyzes a landmark month for the "Texas Triangle," anchored by the Michael & Susan Dell Foundation’s historic $1 billion infrastructure gift and Eli Lilly’s strategic acquisition of Houston-based CrossBridge Bio.

It provides actionable intelligence on the state's rapid pivot toward AI-native clinical solutions and highlights the critical deal flow emerging from local catalysts as Texas cements its position as a global engine for medical innovation and venture liquidity.